Literature DB >> 17177977

Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin.

K Sugita1, K Kabashima, K Atarashi, T Shimauchi, M Kobayashi, Y Tokura.   

Abstract

Skin is an immunological organ consisting of epidermal cells, i.e. keratinocytes and Langerhans cells (LCs, antigen-presenting dendritic cells), and both innate and acquired immune systems operate upon exposure of the skin to various external microbes or their elements. To explore the relationship between innate and acquired immunities in the skin, we investigated whether Toll-like receptor (TLR) ligation of epidermal cells enhances the ability of LCs to present a specific antigen to T cells in mice. LC-containing epidermal cells were incubated with CpG oligonucleotide (TLR9 ligand) modified with trinitrophenyl hapten, and cultured with hapten-primed CD4(+) T cells. TLR9 ligand was capable of enhancing the hapten-presenting ability of LCs when LC-enriched epidermal cells, but not purified LCs, were used as the LC source, suggesting that bystander keratinocytes play a role in the enhancement of LC function. Cultivation of freshly isolated epidermal cells with CpG promoted the expression of major histocompatibility complex (MHC) class II and CD86 molecules on LCs. CpG enhanced the production of interleukin (IL)-1alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumour necrosis factor (TNF)-alpha by primarily cultured keratinocytes. The addition of a cocktail of neutralizing antibodies against these cytokines abrogated the CpG-promoted, antigen-presenting ability of LC-enriched epidermal cells. Moreover, the addition of culture supernatants from CpG-stimulated keratinocytes restored the ability of purified LCs. Our study demonstrated that although the direct effect of CpG on LCs is minimal, LC function can be up-regulated indirectly by cytokines released by CpG-stimulated keratinocytes. This also implies that innate immunity evoked by TLR ligation of keratinocytes enhances acquired immunity comprising LCs and T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17177977      PMCID: PMC1810440          DOI: 10.1111/j.1365-2249.2006.03258.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells.

Authors:  Hironori Matsushima; Nobuo Yamada; Hiroyuki Matsue; Shinji Shimada
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

2.  Epithelial cells pay a Toll for protection.

Authors:  Warren Strober
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

Review 3.  Microbial recognition by Toll-like receptors.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  J Dermatol Sci       Date:  2004-04       Impact factor: 4.563

4.  Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells.

Authors:  Hiroshi Mitsui; Takahiro Watanabe; Hidehisa Saeki; Katsunori Mori; Hideki Fujita; Yayoi Tada; Akihiko Asahina; Koichiro Nakamura; Kunihiko Tamaki
Journal:  J Invest Dermatol       Date:  2004-01       Impact factor: 8.551

5.  Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells.

Authors:  Todd M Schaefer; Kristin Desouza; John V Fahey; Kenneth W Beagley; Charles R Wira
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

6.  Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent.

Authors:  Martin Mempel; Verena Voelcker; Gabriele Köllisch; Christian Plank; Roland Rad; Markus Gerhard; Christina Schnopp; Peter Fraunberger; Autar K Walli; Johannes Ring; Dietrich Abeck; Markus Ollert
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

7.  Expression of functional Toll-like receptor 2 on human epidermal keratinocytes.

Authors:  Kazuhiro Kawai; Hideki Shimura; Masahiro Minagawa; Akiko Ito; Katsuhiro Tomiyama; Masaaki Ito
Journal:  J Dermatol Sci       Date:  2002-12       Impact factor: 4.563

8.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

9.  Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells.

Authors:  M D Witmer-Pack; W Olivier; J Valinsky; G Schuler; R M Steinman
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells.

Authors:  C Heufler; F Koch; G Schuler
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  43 in total

1.  Transdermal immunization using solid-in-oil nanodispersion with CpG oligodeoxynucleotide adjuvants.

Authors:  Momoko Kitaoka; Ayaka Naritomi; Yuya Hirakawa; Noriho Kamiya; Masahiro Goto
Journal:  Pharm Res       Date:  2014-11-01       Impact factor: 4.200

2.  Exposure to in utero lipopolysaccharide induces inflammation in the fetal ovine skin.

Authors:  Matthew W Kemp; Masatoshi Saito; Ilias Nitsos; Alan H Jobe; Suhas G Kallapur; John P Newnham
Journal:  Reprod Sci       Date:  2010-10-05       Impact factor: 3.060

3.  Nasal vestibulitis due to targeted therapies in cancer patients.

Authors:  Janelle N Ruiz; Viswanath Reddy Belum; Christine B Boers-Doets; Mini Kamboj; N Esther Babady; Yi-Wei Tang; Tulio A Valdez; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2015-01-22       Impact factor: 3.603

4.  Cyclooxygenase-2 enhances antimicrobial peptide expression and killing of Staphylococcus aureus.

Authors:  Jamie J Bernard; Richard L Gallo
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 5.  Langerhans cells as targets for immunotherapy against skin cancer.

Authors:  Patrizia Stoitzner; Florian Sparber; Christoph H Tripp
Journal:  Immunol Cell Biol       Date:  2010-03-30       Impact factor: 5.126

6.  TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo.

Authors:  Marein A W P de Jong; Lot de Witte; Menno J Oudhoff; Sonja I Gringhuis; Philippe Gallay; Teunis B H Geijtenbeek
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 7.  Tailored immunity by skin antigen-presenting cells.

Authors:  Clement Levin; Helene Perrin; Behazine Combadiere
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 8.  The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin.

Authors:  Casey T Weaver; Charles O Elson; Lynette A Fouser; Jay K Kolls
Journal:  Annu Rev Pathol       Date:  2012-11-15       Impact factor: 23.472

9.  Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.

Authors:  Lihi Atzmony; Young H Lim; Claire Hamilton; Jonathan S Leventhal; Annette Wagner; Amy S Paller; Keith A Choate
Journal:  J Am Acad Dermatol       Date:  2019-08-23       Impact factor: 11.527

10.  Quiescent innate response to infective filariae by human Langerhans cells suggests a strategy of immune evasion.

Authors:  Alexis Boyd; Sasisekhar Bennuru; Yuanyuan Wang; Vivornpun Sanprasert; Melissa Law; Damien Chaussabel; Thomas B Nutman; Roshanak Tolouei Semnani
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.